



Alzheimer's
Drug Discovery
Foundation



The Association for
Frontotemporal Degeneration
Opening the gateway to help and a cure

REQUEST FOR PROPOSALS

Accelerating DRUG DISCOVERY for Frontotemporal Degeneration

Research investigating the pathologic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. As potential therapies move forward, the need for biomarkers for early diagnosis, to distinguish FTD subtypes, and to monitor disease progression is also critical. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative drug discovery programs and biomarker development for FTD through this Request for Proposals (RFP).

Priority areas for this program include:

- Development and testing of novel high throughput screening assays
- Preclinical testing of novel or repurposed drug candidates
- Proteomics/transcriptomics/metabolomics for FTD biomarkers
- Development/validation of CSF biomarker assays to distinguish TDP-43 or tau-based FTD
- Functional imaging methods that correlate to FTD disease symptoms
- Neurodegeneration and differential connectivity patterns (white and grey matter) in FTD disorders
- Innovate software, algorithm-based approaches to improve quantitative image analysis for FTD
- Innovative pilot clinical trials

MECHANISM(S) OF SUPPORT: ADDF/AFTD will provide grants for one-year duration with the possibility of follow-on funding. Budgets averaging \$150,000-\$200,000 are recommended, but are flexible depending on study design. Applications with extended timelines or larger budgets may be considered on a per project basis. Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program-related investment.

REVIEW PROCESS: The deadline date for applications is **September 22nd, 2015**. Submission of a Letter of Intent (LOI) is required prior to September 8th, 2015. LOIs are reviewed on a rolling basis and can be submitted any time prior to the date above. Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee, including members of AFTD's Medical Advisory Council. Applications from biotechnology companies will also be reviewed by ADDF's external Business Advisory Board.

APPLICATION PROCEDURE

All letters of intent and applications must be submitted electronically at www.alzdiscovery.org. For additional educational resources and access to Contract Research Organizations (CROs), please visit

ADDF ACCESS: <https://addfaccess.ondeckbiotech.com/>

To further discuss scientific or financial aspects of proposals, please contact:

Diana Shineman, PhD, *Director for Scientific Affairs, ADDF*

Phone: 212-901-8007 / E-mail: dshineman@alzdiscovery.org

Nadine Tatton, PhD, *Scientific Director, AFTD*

Phone: 267-514-7221 / Email: ntatton@theaftd.org

For more information regarding the application process, please contact:

Danielle Popow, *Grants Coordinator*

Phone: 212-901-7998 / E-mail: dpopow@alzdiscovery.org